NEDD4 E3 ubiquitin protein ligase serves an important role in cutaneous melanoma occurrence and development

xlomafota13 shared this article with you from Inoreader NEDD4 E3 ubiquitin protein ligase serves an important role in cutaneous melanoma occurrence and development Via Experimental and therapeutic medicine Exp Ther Med. 2021 Dec;22(6):1382. doi: 10.3892/etm.2021.10818. Epub 2021 Sep 28. ABSTRACT The present study aimed to discuss the effects and relative mechanisms of NEDD4 E3 ubiquitin protein ligase (NEDD4) in cutaneous melanoma (CMM) occurrence and development. Clinical cancer and adjacent normal tissues samples were collected to analyze pathological changes and protein expression of NEDD4. Moreover, small interfering (si)RNA was used to knockdown NEDD4 expression in SK-MEL-2 and Malme-3M cells. Cellular proliferation, apoptosis, invasiveness and migration were examined using colony formation, flow cytometric, Transwell and wound-healing assays, respectively. In addition, the relative mRNA and protein expression levels of NEDD4, notch receptor 1 (Notch1) and PTEN were evaluated via reverse transcription-quantitative (RT-q) PCR and western blotting. It was found that NEDD4 mRNA and protein expression were significantly upregulated (bot h P<0.01). Following NEDD4-knockdown, colony number was significantly decreased, while the apoptotic rate was significantly increased, the invasive cell number was significantly inhibited and the wound-healing capacity was significantly decreased. Following si-NEDD4 transfection, RT-qPCR and western blotting revealed that NEDD4 and Notch1 mRNA and protein expression levels were significantly downregulated, while those of PTEN were significantly upregulated in the SK-MEL-2 and Malme-3M cell lines. Collectively, the current results suggest that NEDD4-knockdown effectively suppressed CMM biological activity by regulating the Notch1/PTEN pathway in vitro. PMID:34650630 | PMC:PMC8506948 | DOI:10.3892/etm.2021.10818 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.